Wednesday, June 26, 2013

Possible Cures for Type-1 in the News (June)

Aldesleukin (Proleukin) Starts a Phase-II Clinical Trial

Called DILD1T, this is a 40 person clinical trial.  It started in March 2013, and is expected to finish in January 2015.  It is enrolling adults who have had type-1 diabetes for 3-24 months (so not just honeymooners) in Addenbrooke’s Hospital, Cambridge, UK.  Currently, it is only 12% enrolled, so they have a ways to go.  I'm treating this as a phase-II trial, because of it's size and because Proleukin has already been tested twice in type-1 diabetics (that I know of).

I think that this study involves only one subcutaneous injection (like an insulin injection).

Here is the justification for the study.  The quote is from the researchers, but I've removed some of the medical language:
The vast majority of genes that contribute to susceptibility to type 1 diabetes [are related to] immune regulation and function. In particular, ... the interleukin 2 (IL-2) pathway that regulates T cell activation .... Aldesleukin (Proleukin) is a human recombinant IL-2 product .... There is substantial [research data in tissues/petri dishes, animals, and humans] that ultra low dose IL-2 (aldesleukin) therapy can arrest the autoimmune mediated destruction of pancreatic beta cells by [encouraging] functional T regulatory cells.
The researchers view this study as looking for the optimal dose as a prelude to doing a large phase-III trial.  This is a classic goal of many phase-II trials.  This trial is funded by the Welcome Trust (a big UK operation), JDRF, and the NHS Foundation Trust (which I think is the UK government).

Here are links for this new research:
Web sites: http://www.clinical-trials-type1-diabetes.com  http://public.ukcrn.org.uk/Search/StudyDetail.aspx?StudyID=13846
News: http://www.wellcome.ac.uk/News/Media-office/Press-releases/2013/WTP052844.htm
Facebook: https://www.facebook.com/ClinicalTrialsType1Diabetes
Twitter: https://twitter.com/t1diabetestrial
WHO Registration: http://www.controlled-trials.com/ISRCTN27852285/
US Registration: http://www.clinicaltrials.gov/ct2/show/NCT01827735
Wikipedia on IL-2: http://en.wikipedia.org/wiki/Interleukin_2

I also think it is important to remember that IL-2 has been tested in humans twice before, and has failed both times.  I previously blogged on those trials:
http://cureresearch4type1diabetes.blogspot.com/search/label/IL-2
Clinical Trial Records:
    http://www.clinicaltrials.gov/ct2/show/NCT00336674
    http://www.clinicaltrials.gov/ct2/show/NCT00525889


DiaPep 277's Results from an Extended Phase-III Trial:
No Longer a Cure?

I've been following DiaPep 277 for as long as I've been following type-1 diabetes cures.  When I started, it was already in phase-II trials.  Recently Andromeda Biotech Ltd, the company developing it, has published some phase-III results, and (most recently) some extended phase-III results.  These extended results are from people who were in the phase-III trial for two years, and then continued with the treatment for an additional two years.  The two year extension was "open label", meaning that the patients and doctors knew they were getting the treatment; it was not blinded.

Unfortunately, the results are decidedly mild.  People's A1C numbers dropped by 0.6 (from an average of 7.6 to an average of 7.0.  In terms of improvement of treatment, that's not bad.  I think there is a market for a drug that would lower A1C numbers that amount, but it is not a cure.  There is always hope that future improvements in the treatment will lead to even better A1C improvements (which I think is likely), or even improvements so great they lead to a cure (which I think is very unlikely).  But currently, this is an adjunct treatment, not a cure.  So I expect to stop covering DiaPep 277, unless I see results much larger than are seen here.

news: http://www.globenewswire.com/news-release/2013/06/05/552188/10035325/en/Andromeda-Announces-the-Results-of-an-Extension-to-Its-Phase-III-Study.html

The previously announced results from one of their phase-III trials, which I blogged about here:
http://cureresearch4type1diabetes.blogspot.com/2011/11/andromedas-diapep277-succeeds-in-phase.html
were similarly mild, and much more like a treatment than like a cure. 

Phase-I Trial Resets the Immune System in MS Patients

This news comes from a human trial in multiple sclerosis (MS) patients.  Basically, researchers were able to "reset" the body's immune system, to lower the autoimmunity reaction (the body's attacking it's own cells) by  50%.-75%.  This was in a 9 person phase-I trial in Germany.

To understand why that is important, a little background is needed.  Most researchers believe that MS and Type-1 are related diseases.  In both cases the immune system mistakenly attacks the body's own cells.  In Type-1, it attacks beta cells in the pancreas, and in MS it attacks the myelin sheaths of nerve cells, however the underlying autoimmunity reaction is similar.

Prior to testing on people, this method was tested in mice who had MS and in mice who had type-1 diabetes, and worked on both groups of mice.  However, the human trials were MS only.  But obviously, trials in type-1 diabetic people could be done as well.  In my opinion, should be done.

The idea of resetting (or rebooting) the body's immune system has been tried on type-1 diabetics, and it was successful.  Some of the treated type-1 diabetics did not have to inject insulin for years afterwards.  However, the risk involved is high enough, that these treatments have never moved forward.  At least three different teams (in Brazil, Poland, and China) have run similar trials and gotten similar results.  I have blogged about them before:
http://cureresearch4type1diabetes.blogspot.com/search/label/Burt

Although it is hard to draw a direct comparison, it sounds like the procedure being tested here is much safer, but slightly less effective than the procedure used by Burt, Snarski, Li, etc.  Of course, it might be refined over time to make it more effective or safer, or both.

news: http://scienceblog.com/63715/big-multiple-sclerosis-breakthrough/

Personal Note

In the past, I've posted on my blog what I call a "non-conflict of interest statement" which is this:


  • I don't work for a company involved in medical research; I never have.
  • I don't get paid in any way by any company doing medical research; I never have. And that includes free samples, free travel, or free anything.
  • None of the hours that I have put into my blog, or the posts that I make to any web site, has ever been paid for, nor have I gotten anything free.  (Except for some very nice and heart felt thank-you emails, and those are worth more than money.)
I'm now adding a fourth bullet point:
  • My daughter has type-1 diabetes and participates in clinical trials.  She usually gets some money for participating. I sometimes report on trials that she participates in.  For several reasons, I don't generally reveal what studies she enrolled in (or tried to enroll).  
Why not, you ask?  A couple of reasons.  First  of all, her participation is a two step process.  My wife and I decide the research is safe and that she can participate, and then she decides if she wants to participate.  Therefore, she selects different studies than I would select.  For example, she prefers studies in the summer, and studies that pay well.  I don't want people coming back to me and saying why did she participate in study X rather than study Y?  Second, I get important information from researchers.  I don't want researchers thinking, "his daughter was in Dr. X's trial, but not mine, why is that?"  (Truthfully, the answer is usually, Dr. X paid better, or required less time, or was more convenient, but I don't want to be explaining that.)  Thirdly, I don't want readers of this blog to be thinking "Joshua's daughter isn't in trial X, why should my child be in that one?" or the reverse "Josh's daughter is in trial X, I should get my kid in there, also!"  Our kids are different, and participating in a trial should always be personal decision.  And finally, even participating in a trial might make public health information about my daughter that I don't want public.  For example, enrollment might only be open to people who have a particular side effect, or don't have that side effect, or who are still generating some insulin, or whatever. 

In the last 5 years, I have only blogged on one study that my daughter participated in.  I would expect to blog on only a couple in the next 5 years, so this is a rare thing. 

Joshua Levy
All the views expressed here are those of Joshua Levy, and nothing here is official JDRF or JDCA news, views, policies or opinions. My daughter has type-1 diabetes and participates in clinical trials.  My blog contains a more complete non-conflict of interest statement. Thanks to everyone who helps with the blog. 
Clinical Trials Blog: http://cureresearch4type1diabetes.blogspot.com
Cured in Mice Blog: http://t1dcuredinmice.blogspot.com/

Saturday, June 22, 2013

The Root Cause of Type-1

Some researchers in Boston made a big splash recently by claiming to find the "root cause" of type-1 diabetes.  I've gotten at least two emails asking for my thoughts on the research, so here they are.
One thing that I try to do, is to read the original paper, or at least the abstract, and then describe what the researchers did, what they found, and why it is important.  I've found that the original research often contains valuable information that doesn't make it into press releases, news articles, blog postings, etc.  So I try hard to find that original work.

Unfortunately, I can't do that for this paper.  I've read the abstract a couple of times, and I can't make heads or tails of it.  The abstract assumes a level of knowledge way beyond me.  One thing that did make me nervous was this: it looks like this research was done on people and mice who had transplants to treat type-1 diabetes, and they studied how those people's bodies attacked the transplanted cells.  This makes me nervous because the immune system's attack on a transplanted organ is proper.  It's a foreign invader, after all.  This is different than the immune system's attack on it's own pancreas, which is an error.  I'm not sure learning about the causes of one, is going to teach us what causes the other.  On the other hand, I might be totally misunderstanding what they were doing.  The abstract is opaque to me.

How important is this?

I don't know.  I don't think anyone knows, as yet.  It often takes a few years to confirm that a breakthrough really is the big breakthrough that everyone hoped it was at the start.  Even after we know that this is a big breakthrough, we don't know if it will lead to a cure or not.  The discovery of the smallpox virus (for example) did not lead to the discovery of a cure for smallpox  (and the first smallpox vaccine predated knowledge of the smallpox virus).

In the future, if this leads to a cure (or preventative) for type-1 diabetes, then we will be able to look back and say, "this really was that important".  But there is no reasonable way for us to look into the future and know that this discovery is that important right now.

(I know that's kind of depressing.  Some people react to that by not donating money to research, because they never know which research is going to lead to a cure.  I view it the exact opposite, that it is important to give money to research, so that as many different options can be funded as possible, specifically because we don't know which will lead to a cure.)

What does this mean to me?

I care about a cure for type-1 diabetes, so what does this discovery mean to me?  Basically, a lot more research.  In order to get from a discovery of root cause to a cure, at least three things need to happen.  (a) they need to be sure the discovery is correct and use that discovery to figure out a cure. (b) they need to test that cure in petri dishes, tissue samples, and animals. (c) they need to test it in people.  Now (a) often takes a few years, although sometimes less, and (b) can take anywhere from years to decades, and (c) takes at least 10 years.  So making a few reasonable guesses, I would expect any cure that comes from this discovery to arrive in 15+ years (for an optimistic guess) to 25+ years (for a more reasonable guess).  If this discovery pans out as being important.  And that is a big "if".

One last word.

Curtis Lomax said "This one smells like a lot of hype."  I agree, and I couldn't put it better myself.  In fact, I'm linking to the Lynyrd Skynyrd song "That Smell" as the theme song for this posting:
http://www.youtube.com/watch?v=sV_toedW2L0

Links to the news coverage:
I think this is the paper's abstract:
Joshua Levy
All the views expressed here are those of Joshua Levy, and nothing here is official JDRF or JDCA news, views, policies or opinions. My daughter has type-1 diabetes and participates in clinical trials, which I sometimes blog on. My blog contains a more complete non-conflict of interest statement. Thanks to everyone who helps with the blog. 
Clinical Trials Blog: http://cureresearch4type1diabetes.blogspot.com
Cured in Mice Blog: http://t1dcuredinmice.blogspot.com/

Saturday, May 18, 2013

No Data on Environmental Causes of Type-1


I'm not completely happy with this posting, but I've been working on it for many weeks, and at this point I think it is better to publish what I have, than to continue to struggle with it.  Maybe in the future, will post an improved version.

This posting is a little different from my usual fare.  Instead of discussing specific research results, I'm going to discuss, in more general terms, a subject that has come up repeatedly:

What is causing the increase of type-1 diabetes?

Every six months or so we get a study, government report, or newspaper article claiming that there must be something in the environment which is causing the number of type-1 diabetics to go up, way up. These articles usually follow the same path:
  1. Description of type-1 diabetes as having a genetic and environmental cause [d0].
  2. The number of type-1 diabetics is going up (way up!)
  3. The number of younger type-1 diabetics is going up even more than older ones.
  4. So there must be an environmental cause (usually a toxic chemical) which is growing, and causing the numbers of type-1 diabetics to grow.
They often contain a quote like this one:
Despite a strong genetic component to the susceptibility of T1DM, this marked increase in incidence in different populations within a short period of time cannot be explained by increased transmission of T1DM susceptibility genes. So what is the cause? [r1]
Or like this one:
Essentially all researchers agree that changes of this magnitude cannot be explained by genetics alone. [r6]
(The d-numbered footnotes refer to extra discussion and r-numbered footnotes refer to references, both are at the bottom of the posting.)  Before you get too worried about such news reports, it's best to think about what should be happening.  The simple answer is: of course the rates of type-1 diabetes are going up, and we should all expect that.  Why?  Type-1 diabetes has a large genetic component.  Before 1920, most people who were diagnosed with type-1 diabetes died before they had children.   Now, those people are living longer, happier, richer lives, with children and grandchildren of their own.   So the genetic component of type-1 is becoming more common, and of course the rate of type-1 diabetes is going up [d1].  We certainly would not expect it to be going down or staying the same.

So the the correct response when someone says the rate of type-1 diabetes is going up (way up!) is to yawn, and say "Of course, I would not expect anything else" and "Isn't it great that what was previously a fatal disease is not any more".   However there are still some issues which need some more discussion:
  1. Referring to age at diagnosis: why is the rate of very young type-1 diabetics going up more than the rate of older diabetics?
  2. Is there something in the environment which is contributing to the increase of people with type-1 diabetes, and especially a toxic chemical of some kind?  Even if some of the growth rate is caused by genetics, maybe some of it is not?  
  3. Are sentences like "the increase is too high to be explained by genetics alone" (or similar) supported by the data we have, or are they fear-mongering?
Why are more children getting diagnosed at a younger age?

I'm not going to review it in detail, but I think there is pretty strong evidence that more children are getting diagnosed with type-1 diabetes at a younger age than previously.  For example [r1,r2] both show this. The percentage diagnosed between ages 0 and 5 is going up faster than the more traditional diagnosis between 10 and 20 years old.

The first thing to realize here, is that you would expect this behavior based on the genetics and impact of type-1 diabetes.  Type-1 is not (usually) caused by a single gene.  It is caused by complex groups of genes which, acting together, make it more likely that you will get type-1, and other groups of genes that make it less likely. It is likely [need to specific references here] that there are gene groups that tend to cause type-1 in younger kids, and other gene groups that tend to cause type-1 in older kids.  Prior to the 1920s, everyone who had type-1 diabetes died very close to diagnosis.  So if you had the genes for the age 0-5 type, you had zero chance of having children.  But if you had the genes for a 10-20 year old diagnosis, then maybe you would have children (especially in earlier times, with younger parents).  Obviously, this would be a very small number of births, but it would be higher than zero.  So the genetic "filtering" that type-1 death caused, was stronger for those "younger" genetic variants.  Therefore when the genetic "filtering" is removed, we should expect type-1 diabetes to rise more quickly in younger kids than older kids.  And that is exactly what is seen.

Summary: faster growth in type-1 diabetes diagnosis in younger kids is something that we should be expecting based on the known genetics and lethality of the disease.

Is there something in the environment causing more type-1 diabetes?  
Maybe a toxic chemical?

Obviously, there are a huge number of chemicals out there, and any one of them might increase the incidence of type-1 diabetes.  Even if we proved 1000 (or 10,000) chemicals do not cause type-1 diabetes, it might always be caused by one we have not tested.  So the possibility of chemicals causing type-1 diabetes will always be with us.  But I think there are two important points that should be made here:

First, it is easy to show that a chemical causes type-1 diabetes.

We have an animal model of type-1 diabetes.   It's called the NOD mouse, and has been in widespread use for decades [d3].  The number of these mice who will naturally come down with type-1 diabetes, and when it happens, is well known.  And some of these mice won't come down with the disease, even if most do.  Therefore, any chemical you want to test, you can just give it to these mice, and see if the rate of type-1 diabetes goes up, or if the mice get it more quickly, than the untreated mice. [d4]

This is the kind of mouse-based research that is done all the time, and it isn't even that expensive.  Running a test on 300 mice is vastly cheaper and faster than running a test on even 1 person.

So if anyone really believed that they know which chemical or drug caused type-1 diabetes. They could become famous quickly, easily, and inexpensively by testing their theory in mice. The fact that no one has done this suggests to me that none of the common chemicals sometimes suggested as a cause of type-1 diabetes, really do cause it [d5].

Now, some people will make excuses.  They are likely to say "we can't test chemical X because no one will fund it", but that is untrue for a number of reasons.  Most obviously: non-profits, environmental groups, and government agencies often fund safety research.  But also, companies that produce competitors to a chemical have a strong economic motivation to fund research that the other chemical is unsafe, since that would lead to higher sales of their (competing) chemical.  Finally, remember that fame is an important motivator (in addition to money), and providing strong evidence that a common chemical is unsafe is a sure path to fame in the university, non-profit, and government worlds.

Here are examples of experiments of that kind (could show chemical danger in NOD mice) but did not find any problems:

Trichloroethylene (TCE): http://www.ncbi.nlm.nih.gov/pubmed/18958647 [d6]
Mercury: http://www.ncbi.nlm.nih.gov/pubmed/11529910  [d7]
Bisphenol A (BPA) is a more complex case, which I may cover in a future posting (time permitting).

Second, not a lot of chemicals fit the dosing/timeline profile.

The second problem with blaming a toxic chemical, is that the chemical needs to have a use profile that matches type-1's growth profile, in those countries where we have good data on type-1's growth profile.

For example, it couldn't be DDT.  Because in the USA, DDT use skyrocketed right after World War II, and then dropped to nearly zero in the 1970s.  But the rate of type-1 diabetes continues to grow at a pretty constant rate.  There was no big increase right after WWII and no dropping off in the 1970s.  Similar arguments can be made against lead, PCBs, BPAs, and many other toxins [d9].

But it turns out that type-1 diabetes growth appears to be pretty constant.  More kids are diagnosed each year, but the increase is linear, and there are no big troughs or hills.   (Although [r6] shows some small bumps up and down.)  Indeed, if you look at the whole time period from 1920 to 2012, the growth is pretty constant the whole time (as much as we have data for). [Need to add specific references for this.]  I think that suggests that there is no chemical environmental cause, because the environmental chemicals common to the 1920s are not common now, and visa-versa.  I just don't see a good candidate.  However, since testing the chemical is cheap and easy (see previous discussion), the moment someone does identify a chemical who's use has been steadily growing for the last 90 years, without any large troughs or hills, that chemical could be quickly tested.  And if it happened to match the small ups and downs in the [r6] data in the same countries where that data was gathered, that would be even stronger evidence.

Based on all this, if there is an environmental factor, a toxic chemical is not my leading contender.  I think something like the "hygiene hypothesis" is more likely, or maybe something in the diet, or something related to affluence [d8].

The increase is too high to be explained by genetics alone.

Think about this claim for a minute.  This sentence is based on three pieces of data:
  1. We know how much type-1 diagnosis is increasing.
  2. We know how much it should be increasing, based on genetics.
  3. Therefore, we can see that there is a gap, which must be filled with an environmental cause of growth.  
Of these three statements, only the first is true.  See [r1,r2, r6] and other studies.  Even there, our knowledge is imperfect, but we do have some data about the overall change in the rate of type-1 diagnosis.  But for the next two, we have nothing; absolutely nothing.  Not all the genes that lead to type-1 diabetes have been identified.   Not all the genes that protect against type-1 have been identified.  How these genes interact to cause or avoid type-1 diabetes is not known.  In short, we have no idea, what the levels of type-1 diabetes "should" be, based on genetic susceptibilities.  Obviously, since we don't know 2, we can't know 3.  In my opinion, people who say "there must be an environmental cause for the increase in type-1" are fear mongering, or looking for more research funding. 

Remember: I agree that there is an environmental cause of type-1 diabetes, but I'm also saying that there is no evidence that it is growing. Put another way (with double negatives): I'm not saying that there is no environmental component that causes type-1 diabetes. We know there is [d0]. Rather, I'm saying that there is no evidence that this environmental component is causing the increase in type-1 cases. It is not growing or causing more cases of type-1 diabetes.

Summary:  There is evidence that an environmental component exists, but there is no evidence that the environmental component is causing growth in type-1 diagnosis.

Looking at Genes Specifically

As far as I know, no researcher is looking at the overall genetics of type-1 diabetes to see if the overall genetic change is causing the overall type-1 diagnosis change.  However, there are a couple of studies that look at a single gene specifically [r7].  These studies both looked at a gene highly associated with type-1 diabetes [d10] and they both found that specific gene had become less common in the population.  Not more common, as would be expected.  One study looked at the period from the 1960s to the 2000s, and the other compared the 1980s to the 2000s (roughly).

Proponents of an environmental cause to increases in type-1 diagnosis can point to these studies as support for the idea that the growth is not caused by genetics.  However, these studies provide only the tiniest support.  Neither of these studies actually looked at the total genetic change affecting type-1 diabetes.  Indeed, they couldn't do that, because we don't yet know all the genes that affect type-1 diabetes.  It's like trying to guess if the value of pocket change is going up or down, based on the number of nickels in people's pockets, when you don't even know all the kinds of coins in circulation.

So while these two studies are scientifically interesting, and should form the basis of more research, they are nowhere near the level of knowledge we need to say that the current growth in type-1 diabetes diagnosis is caused by an environmental factor.

Discussion

[d0] We know that the cause of type-1 diabetes has a genetic component, because it is more common in people with relatives who also have type-1 diabetes.   In particular, the closer a relative who has type-1 diabetes, the more likely a person is to have it.  This is a classic sign of a genetic component.  However, we know that there is an environmental component as well, because of "twin studies".  For a purely genetic condition, there should be no cases of identical twins, one with type-1 diabetes and one without.  However, there are.  In fact, in less than half of identical twin pairs do both twins have type-1 diabetes.  It is more common that only one does [r3].  This difference in disease between identical twins is a classic sign of an environmental component.  So it is clear that type-1 diabetes is caused by a combination of both genetics and environmental causes.

[d1] No matter how I phrase it, some people read those last two sentences, and think I'm "blaming" parents for their children's type-1 diabetes.  I'm not, and that's a silly idea in any case.  I'm discussing genetics.  It has nothing to do with blame.  No one decides what DNA to pass to their children.  And it is completely unreasonable to think "well something might go wrong with my kid, so I won't have any."  If people thought like that, no one would ever have children, because something can always go wrong.

[d3] Technically, we have at least three animals models for autoimmunity-based diabetes.  Another is the BB ("Biobreeding") rat [r4], and the third is an animal that given a small dose of a beta cell toxin.  The beta cell die off somehow triggers autoimmunity.  This last technique is quite different that given the animal a large dose of a beta cell toxin (which is more common).  Giving a large dose kills the beta cells, but does not trigger autoimmunity.  It can be used to test insulin replacement, but not autoimmune effects.

[d4] I know a lot of people are frustrated with NOD mice, because cures that work in those mice have failed when used on people.  However, in this case, we are using NOD mice to show danger, rather than improvement.  The "standard of proof" is much lower to show danger, as compared to showing safety and effectiveness.  To show safety and effectiveness most people would require several tests in animals followed by several tests in people.  On the other hand, to show danger, even one or two tests in animals would be enough to convince most people that a chemical was unsafe.  The big frustration of NOD mice (that cures don't work when tried in people) doesn't affect this kind of danger testing, because if the chemical is found unsafe in mice, it's done: no tests in people are needed.

[d5] Basically, the first time I hear someone say that chemical X might cause type-1 diabetes, I look at a calendar.  I then wait a few years.  If no one has published results for the obvious test in NOD mice, then I'm pretty sure chemical X does not cause type-1 diabetes.  I then wait a few more years.  By that point, if no one has published results, then I think it's settled that chemical X does not cause type-1.  A logician will continue to chant "absence of evidence is not evidence of absence," but in the real world, it is.

[d6] A quote from their abstract:
To test whether TCE [Trichloroethylene, a chlorinated hydrocarbon] can exert similar deleterious effects on organ-specific autoimmune diseases, non obese diabetic (NOD) mice were given 5 mg/ml TCE via the drinking water for 12 weeks. ... Contrary to what has been found in systemic models of autoimmunity, TCE did not accelerate the diabetes of NOD mice and may have a protective effect.
[d7] A quote from their abstract:
We found that three weeks of treatment with mercury was also able to significantly suppress the development of insulitis and postpone the onset of diabetes in these mice. Thus, mercury-induced immune activation can counter-regulate the Th1 cell-mediated autoimmune responses and confer a partial protection against autoimmune diabetes in NOD mice.
(Although I don't think people will line up for a clinical study injecting mercury or TCE to delay onset of type-1 diabetes. :-)

[d8] I am not saying that I think the "hygiene hypothesis" is correct. I am saying something much weaker: that the evidence we have for the "hygiene hypothesis" is stronger than the evidence we have for any single, specific chemical causing type-1 diabetes.

[d9] This line of reasoning also tends to exclude breast feeding as an environmental protective against type-1 diabetes.  Breast feeding rates were high in the 1920s, dropped to their lowest in the 1960s, rose in the 1970-1990s, and have been drifting higher since then [r5].  None of that is reflected in type-1 diabetes rates.  If breast feeding protected against type-1, then the type-1 rate would be dropping slightly right now, not rising.  Also, it would have been much higher in the 1960s, than in the 1980s, but the reverse is actually seen.

[d10] I'm not a geneticist.  Both studies dealt with something called "HLA class II".  One study looked at a gene called "HLA-DR, DQ" , while the other looked at a genotype called "HLA-DR3/4-DQB1*0302".  I'm not sure if they were both looking at the same gene, or slightly different genes.  But in either case, they are clearly only looking at a tiny part of the genetics that lead to type-1 diabetes, which is my main point.

References

[r1] Incidence of childhood type 1 diabetes: a worrying trend by Ronald C. W. Ma and Juliana C. N. Chan
October 2009
http://www.nature.com/nrendo/journal/v5/n10/full/nrendo.2009.180.html

[r2] Type 1 Diabetes in Urban Children Skyrockets, Increasing by 70%
Jan 22, 2013
http://www.newswise.com/articles/type-1-diabetes-in-urban-children-skyrockets-increasing-by-70-in-children-under-age-5
http://vitals.nbcnews.com/_news/2013/02/01/16811346-type-1-diabetes-rising-in-kids-study-shows

[r3] http://www.ncbi.nlm.nih.gov/pubmed/22569240
This Italian twins study found:
Genetic contribution to type 1 diabetes susceptibility was 40%, and the shared and individual-specific environmental components were 51% and 9%, respectively.  [I removed the confidance intervals from this sentence, but they are in the original abstract if you want them.]

[r4] Wikipedia on BB rat: http://en.wikipedia.org/wiki/Biobreeding_rat

[r5]
From 200-2008: http://kellymom.com/wp-content/uploads/US_BF_rates.png
From 1850-2000: http://www.historyandpolicy.org/papers/policy-paper-89.html (see Figure 3)

[r6]
http://www.diabetesandenvironment.org/home/incidence/historical

[r7]
http://www.ncbi.nlm.nih.gov/pubmed/18356404
http://www.ncbi.nlm.nih.gov/pubmed/21307077

Sunday, April 28, 2013

Possible Cures for Type-1 in the News (April)



Unfortunately, this is bad news.  But here it is:

Canakinumab and Anakinra Both Fail Phase-II Trials in Honeymooners

Canakinumab (brand name Ilaris, previously known as ACZ885) and Anakinra (brand name Kineret) are different drugs, but they have a lot in common.  Both target IL-1, which is part of the immune system.  Canakinumab is already approved in the US for the treatment of cryopyrin-associated periodic syndromes. Anakinra is already approved in the US for the treatment of rheumatoid arthritis.  Unfortunately, both failed Phase-II trials for type-1 diabetes.  Here is the quote from the abstract:
Canakinumab and anakinra were safe but were not effective as single immunomodulatory drugs in recent-onset type 1 diabetes.
A previous, smaller test of Anakinra had also failed.  

Discussion

I occasionally hear arguments that testing drugs on NOD mice is the wrong approach.  That we should not bother to do that, and just go straight to human testing.  People who make this argument are quick to point out that NOD mice are commonly cured of type-1 diabetes, but none of these cures have worked in people.  They often go a step farther and suggest that maybe NOD mice are so different that they are leading researchers astray.  That a successful mice cure means it won't work on people, and conversely that drugs that work on people might not work on mice.

However, both of these drugs were tested initially in people.  They were never tested (alone) in NOD mice.  And they both failed.  Of course, two examples don't prove anything.  However it does support the idea that curing type-1 diabetes is tough no matter if you test first in mice or first in people.

Abstracts:

Clinical Trial Records:
http://clinicaltrials.gov/ct2/show/NCT00711503

Wikipedia:


Joshua Levy
All the views expressed here are those of Joshua Levy, and nothing here is official JDRF or JDCA news, views, policies or opinions. My blog contains a more complete non-conflict of interest statement. Thanks to everyone who helps with the blog. 
Clinical Trials Blog: http://cureresearch4type1diabetes.blogspot.com
Cured in Mice Blog: http://t1dcuredinmice.blogspot.com/

Tuesday, April 16, 2013

Three Months Of New Clinical Trials (end of 2012)

This is a quick summary of all of the new clinical trials into type-1 that started between October 1st, 2012 and January 1st, 2013. These are trials which were entered into the FDA's clinical trial database for the first time during these three months. You can see the database here: www.clinicaltrials.com

Summary table for the last three months in 2012:

48 Total Clinical Trials
-- ----- -------- ------
 9 Artificial Pancreas  Research into systems that automatically dose based on CGM data. 
 5 CGM                  Research into Continuous (ie. Real Time) Glucose Monitoring.
 2 Transplantation      Research in "classic" transplantation (with immune suppression).
 1 Infrastructure       Research that helps or speeds up future research.  
 1 Prevention           Research aimed at lowering the number of type-1 diagnosis.
 2 Complications        Research aimed at preventing or curing type-1 complications.
10 Treatment            Research into improved BG control technology.
    3 New Test Kits
    2 Delivery
    5 New Insulin
16 Improved Control     Research that lessens the need for BG control technology.
    8 drug
    4 behavioral
    2 nutrient
    1 diet
 2 Cure                 Research aimed at curing type-1 diabetes.

So that means that 4% of new clinical trials were targeted at curing type-1 diabetes.
Both clinical trials aimed at curing type-1 were started by LCT, which I've blogged on before:
http://cureresearch4type1diabetes.blogspot.com/search/label/LCT

Below are some of my comments on some of these clinical trials:

Liraglutide (Victoza) is the Biggest Hot Spot
(but as a treatment, not a cure)


Liraglutide is a drug already approved for type-2 diabetes, however recently there has been a lot of interest in it's ability to help type-1 diabetics control their blood glucose levels.  Five of the clinical trials started in the last quarter of 2012 were testing Liraglutide on type-1 diabetics, and this is in addition to at least four trials which had previously started.

You can read more about the drug here:
http://en.wikipedia.org/wiki/Liraglutide

And my previous blogging on it here:
http://cureresearch4type1diabetes.blogspot.com/search/label/Liraglutide

Effects of Chromium Supplementation on Type-1 Diabetes

This study apparently started in 2007, but was first registered in late 2012, and they expect to finish in 2013. It will enroll 150 people. They are recruiting patients in the Shreveport, Louisiana, USA area, and it is open to people aged 8-21.

Clinical Trial Record: http://www.clinicaltrials.gov/ct2/show/NCT01709123

Exsulin (INGAP) Trial is Officially Suspended

Exsulin corporation has officially suspended their phase-II trial of INGAP (also called Exsulin).  There has not been any new news or scietific papers listed on their web site for 2 years, so I think this potential cure is pretty near to death.

My Previous Blogging: http://cureresearch4type1diabetes.blogspot.com/search/label/INGAP
Clinical Trial Record: http://www.clinicaltrials.gov/ct2/show/NCT00995540

Pet Fish for Better BG Control

One clinical trial is studying the effects of having a pet fish on blood glucose levels in teenagers. (I'm not making this up, and it's not April 1st!) Half the kids enrolled will get a picture of a fish, the other half will get an actual fish, which they are expected to take care of. A1c levels will be compared.  Here is a quote from the researchers:
There is a lack of studies assessing the impact of pet ownership on the health and well-being of adolescents. The process of caring for, loving and being loved by a companion animal could offer direct and/or indirect benefits to the HRQoL [health related quality of life] in children with T1DM. To the investigators' knowledge, there are no studies examining the impact of pet ownership on glycemic control and HRQoL in youth with T1DM.
They are recruiting in Dallas, Texas, USA.

Clinical Trial Record: http://www.clinicaltrials.gov/ct2/show/NCT01733524

Joshua Levy
All the views expressed here are those of Joshua Levy, and nothing here is official JDRF or JDCA news, views, policies or opinions. My blog contains a more complete non-conflict of interest statement. Thanks to everyone who helps with the blog. 
Clinical Trials Blog: http://cureresearch4type1diabetes.blogspot.com
Cured in Mice Blog: http://t1dcuredinmice.blogspot.com/

Friday, February 15, 2013

Possible Cures for Type-1 in the News (Mid Feburary)


Clinical Trial of Diamyd, Ibuprofen ("Advil") and Vitamin D

Diamyd (GAD65) is a protein which is one of the targets of the autoimmune attack that starts off type-1 diabetes. It was developed with the idea that giving it to people with type-1 diabetes would teach their immune systems to not attack their own beta cells. It would be like giving someone who is allergic to peanuts, just a tiny amount of the peanut protein that triggered their allergy, in the hopes that they would build up tolerance.

Unfortunately, although it worked in mice and (to some degree) in phase-II studies in people, it failed in phase-III studies in newly diagnosed type-1 diabetics.   There are still a couple of smaller on going studies.  For example, to see if Diamyd will help prevent type-1 in high risk people who have not yet been diagnosed with the disease.

So that brings us to this study. The idea behind it is:
  1. Give more Diamyd vaccine than was given in the past. About twice as much.
  2. The Vitamin D is supposed to stimulate the part of the immune system that reacts to the Diamyd vaccine, so it makes for a more powerful vaccination effect.
  3. The Ibuprofen ("Advil") lowers the inflammation in the pancreas, which may help save beta cells, and may help the vaccine work better, and may do both.
The study will include 60 children (aged 10 to 18) in the honeymoon phase. They will be followed for 30 months, but expect some results after only 6 months. The participants will be divided into 4 groups of 15. One will be a placebo group, and the other three will each get different combinations of the three treatments.  Since they hope to start in February 2013, I think it is reasonable to expect the 6 month results in the second half of 2015 and the 30 month results by the end of 2017.  That's assuming it takes them 2 years to recruit 60 people.  I have not yet seen a clinical trials record for this, yet.

Press release: http://www.diamyd.com/docs/pressClip.aspx?section=investor&ClipID=738266

More About Diamyd

This is a full PhD thesis that was written based on data from Diamyd's phase-II clinical trial.
http://liu.diva-portal.org/smash/record.jsf?pid=diva2:562438
http://liu.diva-portal.org/smash/get/diva2:562438/FULLTEXT01

Imatinib ("Gleevec" / "Glivec") Starts a Phase-II Clinical Trial

This study has not yet started recruiting, but when it does, it will be a 66 person trial.  It is double blind and placebo controlled.   It is open to honeymooners (first 100 days), including children.  They hope to start in April 2013 and end by April 2017.  I"m not sure of the details, but I think patients will take a pill daily for the first year.  They will have clinic visits monthly for the first year, and twice a year thereafter.

Imatinib is a relatively new cancer drug, which is popular because it targets an enzyme that only cancer cells have, so it is relatively non-toxic to non-cancer cells.  (The buzzword is "targeted".)  The obvious question is why would it be expected to work on type-1 diabetes.   The work done so far in mice suggests that it is a different pathway entirely, which leads to it's effect against type-1.

Some background on why this might work (in order, earliest to most recent):
   Animal models 2007: http://www.fasebj.org/content/21/2/618.abstract
   More mice 2008: http://www.ncbi.nlm.nih.gov/pubmed?term=19015530
   Press release: http://www.ucsf.edu/news/2008/11/4166/cancer-drugs-type-1-diabetes
   Human tissue 2011: http://www.plosone.org/article/info%3Adoi%2F10.1371%2Fjournal.pone.0024831

Notice the progression, and the speed:  First tested in animals in 2007.  First tested in people in 2013.  And remember: this is for a drug that is already approved, for another disease!

Wikipedia: http://en.wikipedia.org/wiki/Imatinib
Clinical Trial Record: http://www.clinicaltrials.gov/ct2/show/NCT01781975

Vitamin D Starts a Phase-II Clinical Trial

So far, there is no evidence that Vitamin D can cure or treat type-1 diabetes, and only a little evidence that it can prevent the disease.  This trial is trying to cure or treat type-1 diabetes by giving Vitamin D during the honeymoon phase.

The trial is being done in Nationwide Children's Hospital (Columbus, Ohio, USA) by Dr.Kathryn J Stephens and Dr. Robert P Hoffman.  It has not started enrollment, but they plan to enroll 54 people.  Half will get vitamin D for 9 months, half will get a placebo.  They hope to have results in March 2014.

I had previously reported on a vitamin D trial, but that was a population based trial, not an intervention trial.  This is an intervention trial, which are typically much higher quality. 

Clinical Trial Record: http://www.clinicaltrials.gov/ct2/show/NCT01724190

A Note About Terminology

I know that some people are very emotional about saying "a person who has type-1 diabetes" vs. saying "a type-1 diabetic", as in "they gave the drug to five people with type-1 diabetes" vs. "they gave the drug to five type-1 diabetics".  Some people object strongly to the second form, because they think that it defines the person by the disease; that it signals in some way that the disease is the person or the person is the disease.

Personally, I usually use the first form, because I prefer it and because I know that some people really object to the second form.  But I'm not fanatical about it, and you will occasionally see me refer to "type-1 diabetics".  I'm not trying to insult anyone when I use the second form.

Joshua Levy
All the views expressed here are those of Joshua Levy, and nothing here is official JDRF or JDCA news, views, policies or opinions. My blog contains a more complete non-conflict of interest statement.   Thanks to everyone who helps with the blog.
Clinical Trials Blog: http://cureresearch4type1diabetes.blogspot.com
Cured in Mice Blog: http://t1dcuredinmice.blogspot.com/

Friday, February 1, 2013

Possible Cures for Type-1 in the News (Early Feburary)


These two news updates are both interesting, and each probably deserves it's own blog entry.  However, since I'm backlogged, I'm putting them together in one posting (together with a Zhao update).  Even after this posting, I'm still a month or more behind.

Results from a Polish Trial of Polyclonal Tregs

What is being tested?  I call this technique "Polyclonal Tregs", but I'm not sure if it has a more official name.  Basically, the researchers remove one specific type of T regulator cell (called a "CD3(+)CD4(+)CD25(high)CD127(-)" T regulator) from a person with type-1 diabetes.  They use these cells to grow a lot more of these cells outside of the body, and then put them back in the body.  Since regulatory T cells naturally regulate the body's immune system, the hope is that they will prevent the autoimmune attack which causes type-1 diabetes.  Previous research in both animals and people has supported the idea that increasing regulator T cells may be a path to a cure.  

The Polish group tested this technique on 10 recently diagnosed (within 2 months) type-1 patients and compared them to 10 patients who did not get the treatment.  4 people got a lower dose (10 × 10^6 Tregs/kg) and 6 people got a high dose (twice as much).  In my opinion, they packed a lot of research into a small trial.  However there were no differences between the lower dose group and the higher dose group.  

Because it was an early trial, safety was an important consideration, and there were no safety related issues.  So that was good.  The publication had effectiveness data from a short (four month) follow up.  Basically:
  • The treated patients generated about 50% more C-peptide than untreated.
  • The treated patients used about half the injected insulin as untreated.
  • A1c levels were about the same.
You can see that here:
http://care.diabetesjournals.org/content/35/9/1817/F1.large.jpg
Remember: grey bars are untreated and white bars are treated.

But remember, these people were within 2 months of diagnosis, and even at the end of the data presented here, were within 7 months of diagnosis, so well within the common honeymoon timeframe.  So I think longer follow on is critical to understanding how important these results are.  If these patients are still using half the insulin that untreated patients are using after 2 years, that would be wonderful.

The good news right now is that they already have one year follow up data, and expect to get it published later in 2013.  Beyond that, they have some improvements to the protocol, and hope to start a follow on trial with an updated protocol soon.  

The Other Polyclonal Treg Study ...

This is not the only study using this "Polyclonal Treg" method.  About two years ago a very similar study started in San Francisco.  Dr. Gitelman is running it, and results are expected in 2016.   I've blogged in the past about this trial here:
http://cureresearch4type1diabetes.blogspot.com/2011/01/possible-cures-for-type-1-in-news-jan.html

This trial has now enrolled its first two groups (out of four total).  I'm told all subjects are doing well with stable pancreas function. The researchers are currently in the middle of the 3rd group, and they anticipate completing the full study enrollment this year.  Each group gets 8 times as large a dose as the previous group so the last group will get about 500 times as much as the first.

... and the Ethics of Experimenting on Children

There is an obvious question here: If both studies started at about the same time, why does one have results 4 years sooner than the other?  I think there are two answers to this question.  The first is pretty simple: the Polish researchers published data covering 4 months after treatment.  The American researchers are gathering data for years.  But that only explains about 20 months of difference.

The second reason might be more important: The American researchers are only enrolling adults, people over 18 years old.  The Polish researchers enrolled children, 5-18 years old.  Obviously, when you are looking for recently diagnosed type-1 diabetics, there are a lot more to be found in the 5-18 year range than the 18+ year range.  By limiting recruitment to adults, the Americans have a much smaller pool of people, and it will therefore take them much longer to fully populate their trial.

But why are the American researchers only enrolling adults?  That answer is a combination of ethics and previous experience.  There is a general ethical principal (enshrined in various FDA rules, and international guidelines) that research should be done on adults first, before it is done on children, if that is feasible.  That makes a lot of sense, of course, but here we see the impact.  For a disease like type-1 diabetes, it is possible to recruit recently diagnosed adults, but it is far harder and slower.  So if we insist that the first bunch of patients are adults, it serves to slow down research disproportionately.

The Polish group had previously run a similar clinical trial in adults with a different disease (graft vs. host disease).  Now measuring safety in adults with one disease is not exactly the same as measuring safety in adults with a different disease, but it is similar.  Therefore, they could recruit children based on the safety profile with adults in the previous study.  Also, they could test different doses more quickly, again based on the previous experience.

Abstract: http://www.ncbi.nlm.nih.gov/pubmed/22723342
Full paper: http://care.diabetesjournals.org/content/35/9/1817.long (Thanks to ADA's DiabetesCare.)

Clinical trial record for the American study: http://clinicaltrials.gov/show/nct01210664

More Details on This Treatment

One way to view the immune system is a balancing act.  We want aggressive immune cells to attack foreign cells, but overly aggressive cells might attack our own beta cells and cause type-1 diabetes.  So we also want regulatory immune cells to keep the aggressive cells in line.  But we don't want those cells too strong, because then they would prevent an attack on the foreign cells.  In this view, type-1 diabetes can be seen as a too aggressive immune system, and therefor boosting the regulatory side might be a cure.

The regulatory cells which are been grown out (or "amplified" might be a better word) are general purpose regulatory cells.  That's a good place to start, but it would be even better if the researchers could multiply a regulatory cell that specifically targeted autoimmune cells (the "bad" cells that are attacking the wrong target).  Unfortunately, the technology is not there yet, although people are working on it.  But in any case, we need to start somewhere.

Below is a link to a study that suggests that newly diagnosed type-1 diabetic children have lower levels of these T regulator cells, than children who do not have type-1 diabetes.  (Although it was a small group.)  http://www.ncbi.nlm.nih.gov/pubmed/19454187

A Note About "Remission"

Some type-1 researchers use the term "remission".  Specifically, they use it to mean "Uses less than 1/2 a unit of insulin per kg of body weight per day".   Don't be confused.  Non-researchers think of "remission" as meaning "doesn't use insulin", but that is NOT how researchers use the term.   If your child weighs 40 kg (about 88 pounds), and uses 20 units of insulin, or less, then they are "in remission", and this does happen to some people during the honeymoon.


Perle Bioscience Starts two Phase-III Clinical Trials of Cyclosporine and Lansoprazole ("Prevacid")

Dr. Claresa Levetan at Perl Bioscience has filed the paperwork to start two very interesting studies.   Both studies are looking at a combination of Cyclosporine and Lansoprazole (commonly known as "Prevacid") as a cure for type-1 diabetes.  The two studies are identical, but one recruits honeymooners and the other established type-1 diabetics.  These are combo clinical trials exactly like many people have been hoping for, for years:  Cyclosporine is known to stop the autoimmune attack and Lansoprazole is known to encourage the natural regrowth of pancreatic beta cells.  Both are approved drugs (for other diseases).  Lansoprazole (as "Prevacid") is over the counter, so has a very good safety profile.  Cyclosporine has a more complex safety profile.  I'm sure if this study pans out, the relative safety of Cyclosporine is going to be an important topic of discussion.

Both studies are expected to enroll 200 people (half getting the treatment and half getting placebo).  They plan to start in September 2013 and end by March 2014 (so very quick).   There will be four groups: one group getting both drugs, one just getting Cyclosporine, one just getting Lansoprazole, and one getting neither.  This is good experimental design for a two drug combination. They will measure C-peptide in response to eating, A1c, and insulin usage.

Note on phases: The researchers running this trial have described it as a "phase-III trial", however I consider it a phase-II trial.  Why the difference?  For me, size is the most important issue.  At 200 people, it is right on the border between what I consider phase-II and phase-III for clinical trials aimed at curing type-1 diabetes.  (For comparison, all eight recent phase-III trials have involved 300 people.  That seems to be the magic number for FDA approval as a pivotal trial in type-1 diabetes.)  Also, this combination of drugs has never (to my knowledge) been tested on type-1 diabetics before.  Since both drugs are approved for other things, I'm willing to call it phase-II (rather than phase-I), but with zero experience with the combination, I'm not willing to call it a phase-III.

Of course, the important question is not what I consider the trial, or even what the researchers consider the trial, the real question is how will the FDA consider the trial?  That remains to be seen, but remember: since both drugs are already approved for other uses, your doctor can prescribe this combination right now.  It would be an off label use.

The researcher working on this, Dr. Claresa Levetan, previously worked on CureDM, and sold that to Sanofi-Aventis two years ago.  My understanding is that they are developing the CureDM technology (a peptide which stimulates beta cell development) for the type-2 market.

Wikipedia on Lansoprazole: http://en.wikipedia.org/wiki/Lansoprazole
Wikipedia on Cyclosporine: http://en.wikipedia.org/wiki/Cyclosporine
Clinical Trial Record (Honeymoon): http://www.clinicaltrials.gov/ct2/show/NCT01762644
Clinical Trial Record (Established): http://www.clinicaltrials.gov/ct2/show/NCT01762657

More Background on
http://www.ncbi.nlm.nih.gov/pubmed?term=3125434

Zhao Updates from Spain 

Previous blogging on Zhao's "Stem Educator" is here:
http://cureresearch4type1diabetes.blogspot.com/search/label/Zhao

These two links go to Spanish language news reports on people getting treated with the Stem Educator in Spain.  I found that using Chrome to translate them into English worked pretty well for me:
http://www.rtpa.es/ciencia:El-HUCA-busca-financiacion-para-un-proyecto-pionero-en-el-tratamiento-de-la-diabetes_111357993752.html
http://diabetesmadrid.org/2012/12/05/el-huca-lidera-la-lucha-contra-la-diabetes/

The basic summary is that the clinical trial in Spain has started.  Two patients had their first session of stem cell educator therapy in December 2012.  The plan is to treat a total of 30 people.  (Not sure how many are placebo and how many will get the real treatment.)  The two treated so far have had type-1 for over 10 years.  This trial is expected to end in September 2014, but we will not know with certainty until it is fully enrolled.

JDCA State of the Cure 2012


The JDCA (Juvenile Diabetes Cure Alliance) is trying to focus more research dollars into cure research (as opposed to treatment research, cause research, etc.)  They publish research papers, which are often quite interesting.  They use my blog as a source, and we sometimes discuss various research issues.

The article below is their year end summary, and well worth a read.  Although I certainly don't agree with everything in it, it is a rich source of information.  (I especially object to their not including Dr. Zhao's research as a possible cure, and JDCA did cover Zhao in a report after this one.)

http://www.thejdca.org/wp-content/uploads/2012/11/State-of-the-Cure-report.pdf

A Final Note

In the past, I have included a specific "thank you" when people reviewed a blog posting, provided information for it, or pointed out the news to me (when only one person did so).  Unfortunately, keeping track of who helped with what, and also making sure it was OK to thank them by name, has become too much of a burden.
So I'm going to stop doing that.

I'm very sorry I will not be able to thank people individually for their help in writing this blog.  But I do want to thank:
  • My wife, who improves my English, and puts up with the hours I spend yelling at the computer when I should be talking with her.
  • All the researchers who have answered my questions and provided extra information.
  • Everyone who emails me when they see news that I should cover.

Joshua Levy
All the views expressed here are those of Joshua Levy, and nothing here is official JDRF or JDCA news, views, policies or opinions. My blog contains a more complete non-conflict of interest statement. 
Clinical Trials Blog: http://cureresearch4type1diabetes.blogspot.com
Cured in Mice Blog: http://t1dcuredinmice.blogspot.com/